Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study to Evaluate the Efficacy and Safety of Kumorixilib Combined With Capecitabine and Letrozole as Neoadjuvant Therapy for HR-Positive, HER2-Negative Breast Cancer

NCT07691333 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT07691333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07691333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study to Evaluate the Efficacy and Safety of Kumorixilib Combined With Capecitabine and Letrozole as Neoadjuvant Therapy for HR-Positive, HER2-Negative Breast Cancer
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
April 30, 2028
Enrollment
35 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, hr+/her2- breast cancer